Cytek Biosciences, Inc.
Income Statement
| Line Item | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $46.6M | $44.9M | $58.2M | $48.0M | $49.7M | $37.1M | $-112.7M | $40.5M |
| Cost of Revenue | $21.2M | $21.8M | $25.2M | $20.8M | $21.5M | $16.1M | $19.0M | $13.6M |
| Gross Profit | $25.4M | $23.0M | $33.0M | $27.2M | $28.2M | $21.0M | $29.4M | $26.9M |
| Gross Margin | 54.6% | 51.3% | 56.8% | 56.6% | 56.7% | 56.7% | -26.1% | 66.4% |
| Operating Expenses | ||||||||
| Research & Development | $10.0M | $9.8M | $10.9M | $11.2M | $12.1M | $10.0M | $9.7M | $8.7M |
| SG&A Expense | $11.7M | $11.4M | $10.8M | $10.4M | $10.8M | $12.1M | $10.5M | $8.0M |
| Operating Income | $-8.5M | $-10.7M | $-136.0K | $-6.4M | $-9.1M | $-12.2M | $84.0K | $1.4M |
| Operating Margin | -18.3% | -23.9% | -0.2% | -13.4% | -18.4% | -32.8% | -0.1% | 3.4% |
| Interest Expense | — | $441.0K | $394.0K | $595.0K | $409.0K | $673.0K | $687.0K | $649.0K |
| Pretax Income | $-7.2M | $-9.0M | $4.1M | $-4.2M | $-6.6M | $-9.0M | $4.1M | $1.9M |
| Income Tax Expense | $3.2M | $-2.8M | $-1.4M | $2.3M | $-2.2M | $-2.2M | $396.0K | $224.0K |
| Net Income | $-10.4M | $-6.2M | $5.5M | $-6.5M | $-4.4M | $-6.8M | $3.7M | $1.6M |
| Net Margin | -22.4% | -13.8% | 9.4% | -13.5% | -8.8% | -18.4% | -3.3% | 4.0% |
| EPS (Basic) | $-0.08 | $-0.05 | $0.04 | $-0.05 | $-0.03 | $-0.05 | $0.01 | $-0.01 |
| EPS (Diluted) | $-0.08 | $-0.05 | $0.04 | $-0.05 | $-0.03 | $-0.05 | $0.01 | $-0.01 |
| Shares Outstanding (Basic) | 131.4M | 130.9M | 135.3M | 136.2M | 135.9M | 135.5M | 134.5M | 134.7M |
| Shares Outstanding (Diluted) | 131.4M | 130.9M | 135.3M | 136.2M | 135.9M | 135.5M | 138.6M | 138.7M |
| Dividends Per Share | — | — | — | — | — | — | — | — |